SFSviatlana Filitaryna

Sviatlana Filitaryna

*This is an algorithmically generated author record based on publicly available information.

Sviatlana Filitaryna has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The effect of hemodialysis on intraocular pressure and ocular perfusion pressure: an interdisciplinary review

    by Sviatlana Filitaryna, Monika Wiatr, Magda Marciniak, Cezary Orzechowski, Michał Gutowski, Monika Kałwak, Aleksandra Foryś, Wojciech Wojas, Justyna Żabicka, Kinga Lichtarska, et al.

    Hemodialysis, as the most commonly used method of renal replacement therapy, may induce changes in intraocular pressure. A hemodialysis-associated increase in intraocular pressure has been reported primarily in patients with impaired aqueous humor outflow, including those with narrow or closed iridocorneal angles and those with primary or secondary glaucoma, especially neovascular or pseudoexfoliative glaucoma. One of the main mechanisms underlying intraocular pressure elevation is considered to be a non-synchronous decrease in blood and intraocular fluid osmolality, leading to a transient osmotic gradient and fluid shift into the eyeball. Hemodialysis may also affect ocular perfusion pressure, and its reduction may increase optic nerve susceptibility to damage even when intraocular pressure remains within normal limits. Fluctuations in both intraocular pressure and ocular perfusion pressure represent a clinically significant but under recognized concern in patients at risk. This review highlights the importance of interdisciplinary collaboration between nephrologists and ophthalmologists, while existing knowledge gaps justify further research in this area.

  • Open Access

    Selected Cutaneous and Mucocutaneous Manifestations Associated with Inflammatory Bowel Disease: Diagnostic and Therapeutic Implications

    by Magda Marciniak, Sviatlana Filitaryna, Monika Wiatr, Cezary Orzechowski, Michał Gutowski, Monika Kałwak, Aleksandra Foryś, Wojciech Wojas, Justyna Żabicka, Kinga Lichtarska, et al.

    Inflammatory bowel disease, including Crohn’s disease and ulcerative colitis, comprises chronic inflammatory disorders of the gastrointestinal tract. In addition to intestinal symptoms, IBD may be accompanied by numerous extraintestinal manifestations, including cutaneous and mucocutaneous lesions. The most commonly reported dermatological manifestations include erythema nodosum, pyoderma gangrenosum, and oral lesions associated with Crohn’s disease. Cutaneous manifestations may precede the diagnosis of IBD; therefore, their recognition is important not only for dermatologists, but also for specialists in internal medicine and gastroenterology. Early identification of these manifestations may contribute to earlier diagnosis of the underlying disease and implementation of appropriate treatment. This review discusses selected, clinically relevant cutaneous and mucocutaneous manifestations in the course of IBD, with particular emphasis on their epidemiology, diagnostic criteria, clinical presentation, and therapeutic options.

  • Open Access

    RETHINKING PRIMARY SPONTANEOUS PNEUMOTHORAX IN CHILDREN AND ADOLESCENTS: CURRENT EVIDENCE AND EVOLVING MANAGEMENT STRATEGIES

    by Michał Gutowski, Cezary Orzechowski, Monika Kałwak, Sviatlana Filitaryna, Monika Wiatr, Magda Marciniak, Aleksandra Foryś, Justyna Żabicka, Kinga Lichtarska, Patryk Dłubis, et al.

    Primary spontaneous pneumothorax (PSP) is increasingly identified in adolescents, but its management is still debated due to a lack of robust pediatric data and a reliance on adult guidelines. As a result, pediatric centers show significant differences in their approaches to diagnosis, imaging, treatment decisions, surgical timing, and follow-up care. This review outlines the latest evidence on diagnosing and managing pediatric primary spontaneous pneumothorax (PSP). Current research favors a symptom-based diagnostic method, with chest X-rays serving as the primary imaging tool. Routine CT scans are discouraged because they expose children to unnecessary radiation, rarely change initial treatment plans, and fail to reliably predict recurrence based on radiographic blebs. Ultimately, treatment strategies should be customized based on the patient's clinical stability rather than relying solely on the size of the pneumothorax. Observation is a suitable approach for certain stable patients with small to moderate PSP. Conversely, treatments such as needle aspiration, chest tube drainage, or surgery should be utilized only for patients experiencing severe symptoms, continuous air leaks, unsuccessful lung re-expansion, or recurring pneumothorax. When surgical intervention is required, video-assisted thoracoscopic surgery is the favored method, though post-operative recurrence rates are higher in children compared to adults. Current evidence indicates a lack of standardized follow-up procedures for pediatric patients. Therefore, follow-up care should center on the early detection of recurrences, which typically happen within the first year of the initial event. The use of routine computed tomography for follow-up is not recommended. Additionally, patient counseling needs to address smoking and vaping cessation, guidelines for resuming physical activity, postponing air travel until imaging shows complete healing, and avoiding compressed-air diving due to a lifelong recurrence risk. Although recent progress has been made, significant knowledge gaps persist concerning the ideal selection of patients for conservative rather than surgical treatment, risk factors for recurrence, uniform follow-up protocols, and long-term results. To develop evidence-based, child-specific guidelines for diagnosing and treating primary spontaneous pneumothorax, future prospective multicenter pediatric studies are essential.

  • Open Access

    VITAMIN D STATUS AND ITS IMPACT ON DISEASE ACTIVITY IN PEDIATRIC-ONSET MULTIPLE SCLEROSIS: A COMPREHENSIVE NARRATIVE REVIEW

    by Justyna Zabicka, Kinga Lichtarska, Michał Gutowski, Cezary Orzechowski, Sviatlana Filitaryna, Monika Kałwak, Magda Marciniak, Aleksandra Foryś, Monika Wiatr, Wojciech Wojas, et al.

    Pediatric-onset multiple sclerosis (POMS), defined as the onset of multiple sclerosis (MS) before the age of 18 years, accounts for approximately 3–5% of all MS cases and is characterized by a markedly inflammatory disease course with high relapse rates and earlier accrual of cognitive and physical disability than adult-onset disease [22–25]. Among the modifiable environmental risk factors implicated in MS susceptibility and activity, vitamin D has attracted sustained scientific attention [3,4,48]. This narrative review synthesizes current evidence on the role of vitamin D in POMS, integrating epidemiological, immunological, genetic (Mendelian randomization), observational and interventional data. Mendelian randomization analyses provide robust evidence for a causal relationship between genetically lowered 25-hydroxyvitamin D [25(OH)D] concentrations and increased POMS susceptibility (OR 0.72, 95% CI 0.55–0.94, p = 0.02 for higher genetically predicted vitamin D) [1]. Observational studies consistently report that each 10 ng/mL (25 nmol/L) increase in serum 25(OH)D is associated with an approximately 34% reduction in subsequent relapse rate in POMS [2], and with comparable reductions in new T2 and gadolinium-enhancing magnetic resonance imaging (MRI) lesions in mixed adult-pediatric cohorts [17,19]. Despite biologically plausible immunomodulatory and remyelinating effects demonstrated in experimental models [36–39], randomized controlled trials of vitamin D supplementation have predominantly failed to meet primary clinical endpoints, with positive signals largely confined to secondary MRI outcomes [5,6,41–43]. Pediatric-specific randomized data remain scarce. Current expert consensus supports avoidance of insufficiency (25(OH)D < 20 ng/mL) and targeting serum levels of 30–50 ng/mL (75–125 nmol/L) using daily doses up to 2000–4000 IU of cholecalciferol, with biochemical monitoring [3,27,28,50]. Future research priorities include adequately powered pediatric trials, harmonized dosing protocols, and long-term safety surveillance.

  • Open Access

    RHINITIS MEDICAMENTOSA: PATHOPHYSIOLOGY, CLINICAL MANIFESTATIONS, AND CURRENT MANAGEMENTS STRATEGIES

    by Monika Kałwak, Patryk Dłubis, Sviatlana Filitaryna, Monika Wiatr, Magda Marciniak, Cezary Orzechowski, Michał Gutowski, Wojciech Wojas, Justyna Żabicka, Kinga Lichtarska, et al.

    Background: Rhinitis medicamentosa (RM) is a non-allergic condition caused by the prolonged use of topical nasal decongestants. Despite its prevalence, it remains frequently underdiagnosed in clinical practice. Objectives: This review synthesizes current knowledge on the pathophysiology, diagnostic criteria, and multifaceted treatment approaches for RM. Methods: A comprehensive literature search was conducted across PubMed (up to 2026) focusing on alpha-adrenergic agonist-induced mucosal changes and therapeutic interventions. Results: Chronic administration of sympathomimetics, such as xylometazoline, leads to adrenoceptor downregulation, secondary vasodilation, and permanent mucosal remodelling. Clinical presentation is characterized by rebound congestion and tachyphylaxis. Management centers on immediate or tapered decongestant cessation, supplemented by intranasal corticosteroids. In refractory cases involving turbinate hypertrophy, surgical intervention (e.g., conchoplasty) remains a definitive option. Conclusions: RM represents a significant clinical challenge. Increasing clinical awareness and patient education regarding the risk of decongestant overuse are crucial for prevention and successful long-term outcomes.

  • Open Access

    ATOPIC DERMATITIS: FROM PATHOGENESIS TO TARGETED THERAPEUTIC STRATEGIES

    by Monika Kałwak, Aleksandra Foryś, Sviatlana Filitaryna, Monika Wiatr, Magda Marciniak, Cezary Orzechowski, Michał Gutowski, Wojciech Wojas, Justyna Żabicka, Kinga Lichtarska, et al.

    Atopic dermatitis (AD), also referred to as atopic eczema, is a common chronic inflammatory skin disorder characterized by intense pruritus, xerosis, and recurrent eczematous lesions. It significantly affects patients’ quality of life and poses a considerable clinical burden. This review aims to summarize current knowledge on the pathogenesis of AD and highlight recent advances in targeted therapeutic strategies. A narrative review of recent literature was conducted, focusing on immunological pathways and modern treatment approaches. The analysis emphasizes the central role of immune dysregulation, particularly involving type 2 helper T-cell responses, impaired skin barrier function associated with filaggrin deficiency, and genetic predisposition in disease development. Environmental factors and microbiome alterations also contribute to disease exacerbation. Recent therapeutic progress has introduced targeted treatments, including biologic agents and Janus kinase inhibitors, which have demonstrated high efficacy and safety profiles. These innovations have significantly improved disease control and patient outcomes. In conclusion, improved understanding of AD pathogenesis supports the development of personalized and more effective management strategies.